Loading clinical trials...
Loading clinical trials...
The study treatment period is 15 days in length and includes patients with pituitary Cushing's disease who are candidates for surgical intervention as well as and patients who have recurrent Cushing's...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT05382156 · Endogenous Cushing's Syndrome
NCT05307328 · Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, and more
NCT03162068 · Osteoporosis in Cushing's Syndrome, Osteoporosis in Post-menopausal Women
NCT03880513 · Endogenous Cushing's Syndrome
NCT02468193 · Cushing's Syndrome, Ectopic Corticotropin Syndrome, and more
Cedars-Sinai Pituitary Center
Los Angeles, California
Massachusetts General Hospital NE Unit
Boston, Massachusetts
Oregon Health & Science University
Portland, Oregon
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions